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Abstract	
As	inhibitors	of	3‐hydroxy‐3‐methylglutaryl‐CoA	reductase,	statins	are	an	important	first‐
line	 treatment	 for	 hypercholesterolemia.	 However,	 a	 recognized	 side‐effect	 of	 statin	
therapy	is	myopathy,	which	in	severe	cases	can	present	as	potentially	fatal	rhabdomyolysis.	
This	represents	an	important	impediment	to	successful	statin	therapy,	and	despite	decades	
of	research	the	molecular	mechanisms	underlying	this	side‐effect	remain	unclear.	Current	
evidence	supports	a	role	for	reduced	levels	of	mevalonate	pathway	intermediates,	with	the	
most	 accepted	 hypothesis	 being	 a	 reduction	 in	 isoprenoids	 formation,	 leading	 to	 faulty	
post‐translational	modifications	of	membrane‐associated	proteins.	We	have	undertaken	a	
comprehensive	 analysis	 of	 the	 impact	 of	 nine	 statins	 on	 two	 human	 cell	 lines;	 Huh7	
hepatoma	 and	 RD	 rhabdomyosarcoma.	 In	 both	 cell	 lines,	 concentration‐dependent	
inhibition	 of	 prenylation	 is	 observed	 for	 cerivastatin	 and	 simvastatin,	 which	 could	 be	
rescued	with	 the	 pathway	 intermediate	mevalonate;	 in	 general,	 muscle	 cells	 were	more	
sensitive	 to	 this	 effect,	 as	 measured	 by	 the	 levels	 of	 unprenylated	 Rap1A,	 a	 marker	 for	
prenylation	 by	 geranylgeranyl	 transferase	 I.	 Concentration‐dependent	 toxicity	 was	
observed	in	both	cell	lines,	with	muscle	cells	again	being	more	sensitive.	Importantly,	there	
was	no	correlation	between	inhibition	of	prenylation	and	cell	toxicity,	suggesting	they	are	
not	 causally	 linked.	 The	 lack	 of	 a	 causal	 relationship	 was	 confirmed	 by	 the	 absence	 of	
cytotoxicity	 in	 all	 cell	 lines	 following	 exposure	 to	 specific	 inhibitors	 of	 geranylgeranyl	
transferase	I	and	II,	and	farnesyl	transferase.	As	such,	we	provide	strong	evidence	against	
the	 commonly	 accepted	 hypothesis	 linking	 inhibition	 of	 prenylation	 and	 statin‐mediated	
toxicity,	with	the	two	processes	likely	to	be	simultaneous	but	independent.	 	
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1. Introduction	
Statins	 remain	 a	 front	 line	 treatment	 for	 the	 prevention	 of	 cardiovascular	 disease.	 As	
inhibitors	 of	 3‐hydroxy‐3‐methylglutaryl‐CoA	 reductase	 (HMGCR),	 the	 rate	 limiting	
enzyme	 of	 cholesterol	 synthesis,	 they	 significantly	 reduce	 cholesterol	 production	 in	 the	
liver,	and	circulating	cholesterol	levels	(Goldstein	and	Brown	1990;	Istvan	and	Deisenhofer	
2001).	 However,	 significant	 adverse‐effects	 associated	 with	 statin	 usage	 either	 limit	 or	
preclude	 their	 utility	 in	 some	 individuals.	 The	major	 statin‐mediated	 adverse	 effects	 are	
myopathies,	 muscle	 related	 side‐effects	 that	 can	 range	 from	 mild	 (muscle	 aches	 and	
cramps)	 to	 severe	 (rhabdomyolysis).	 While	 in	 some	 patients	 these	 myopathies	 are	
tolerable,	 in	many	cases	they	necessitate	the	withdrawal	of	 treatment,	and	 in	some	cases	
rhabdomyolysis	can	be	fatal	(Arora	et	al.	2006;	Graham	et	al.	2004).		
Cholesterol	 biosynthesis	 is	 one	 endpoint	 within	 the	 mevalonate	 pathway,	 which	 is	
responsible	for	the	production	of	a	number	of	biologically‐important	molecules,	 including	
cholesterol,	ubiquinone,	phosphodolichol	and	the	isoprenoids	farnesyl	and	geranylgeranyl	
pyrophosphate	 (FPP	 and	GGPP;	 Fig.	 1).	 As	HMGCR	 sits	within	 the	 shared	 portion	 of	 this	
pathway,	its	inhibition	by	statins	potentially	impacts	upon	all	these	biosynthetic	endpoints	
(Takemoto	and	Liao	2001).	
The	mechanism	that	underlies	 statin	 toxicity	 is	not	 fully	understood,	but	 is	 likely	 to	be	a	
direct	 consequence	 of	 the	 inhibition	 of	 the	mevalonate	 pathway,	 rather	 than	 an	 indirect	
transcription‐mediated	 effect	 (Howe	 et	 al.	 2011),	 since	 mevalonate	 supplementation	
prevents	 toxicity	 both	 in	 vitro	 (Johnson	 et	 al.	 2004)	 and	 in	 vivo	 (Westwood	 et	 al.	 2008).	
Depletion	 of	 cholesterol	 is	 not	 thought	 to	 be	 a	 primary	 cause	 of	 myopathy	 as	 squalene	
synthase	inhibitors,	which	block	the	first	step	in	the	cholesterol	branch	of	the	mevalonate	
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pathway	 are	 not	 myotoxic	 (Nishimoto	 et	 al.	 2007;	 Nishimoto	 et	 al.	 2003).	 In	 addition,	
insects	 and	 nematodes	 both	 lack	 the	 cholesterol	 biosynthetic	 arm	 of	 the	 mevalonate	
pathway,	but	faithfully	reproduce	the	other	biosynthetic	endpoints	seen	in	mammals;	they	
thus	 represent	 ideal	 models	 to	 examine	 non‐cholesterol‐dependent	 effects	 of	 statins.	
Experiments	 in	Drosophila	melanogaster	 and	Caenorhabditis	elegans	 are	 able	 to	 replicate	
both	some	of	the	beneficial	effects	(for	example,	cardioprotection)	and	the	adverse	effects	
of	statins,	demonstrating	that	 these	endpoints	are	not	reliant	on	the	cholesterol‐lowering	
effects	of	these	drugs	(Morck	et	al.	2009;	Rauthan	et	al.	2013;	Spindler	et	al.	2012).	Taken	
together,	 this	 evidence	 is	 consistent	 with	 myopathic	 adverse	 endpoints	 being	 mediated	
through	 inhibition	 of	 one	 (or	 more)	 of	 the	 alternate	 biosynthetic	 endpoints	 of	 the	
mevalonate	 pathway.	 Evidence	 exists	 to	 support	 disruption	 of	 ubiquinone	 (Marcoff	 and	
Thompson	2007),	dolichol‐mediated	N‐linked	glycosylation	(Mullen	et	al.	2010;	Siddals	et	
al.	2004)	and	prenylation	(Blanco‐Colio	et	al.	2002;	Guijarro	et	al.	1998;	Itagaki	et	al.	2009;	
Matzno	et	al.	2005;	Sakamoto	et	al.	2011;	Satoh	et	al.	2001)	following	statin	treatment,	but	
it	 is	as	yet	unclear	as	to	which,	if	any,	 is	the	primary	determinant	of	the	observed	human	
myopathies.		
In	the	current	work,	we	have	used	secondary	cell	lines	as	a	tool	to	delineate	the	molecular	
mechanisms	 underlying	 statin‐induced	myopathy,	 and	 in	 particular	 the	 potential	 role	 of	
inhibition	 of	 prenylation.	 We	 have	 demonstrated	 that	 while	 liver	 and	 muscle	 cell	 lines	
differ	in	their	sensitivity	to	statins	both	in	terms	of	cell	death	and	reduction	in	prenylation,	
these	are	not	causally	 linked,	since	cells	 inhibited	 for	prenylation	do	not	show	a	reduced	
viability	or	morphological	defects.	As	such,	we	provide	strong	evidence	that	statin‐induced	
myopathy	is	not	mediated	via	inhibition	of	prenylation,	as	commonly	assumed.	
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2. Materials	and	Methods	
2.1. Materials	–	Statins	were	obtained	from	the	following	sources:	simvastatin	(lactone),	
lovastatin,	 and	 fluvastatin	 from	 Calbiochem	 (Merck	 KGaA,	 Darmstadt,	 Germany);	
atorvastatin	 and	 rosuvastatin	 from	Molekula	 (Dorset,	 UK);	 and	 cerivastatin,	 simvastatin	
(sodium	salt)	and	pravastatin	from	Sequoia	Research	Products	Limited	(Pangbourne,	UK).	
Mevalonate	 (lithium	 salt),	 and	 the	 prenyltransferase	 inhibitors	 GGTI‐2133,	 FT‐277	 and	
perillyl	alcohol	were	purchased	from	SigmaAldrich	(Dorset,	UK).	
Primary	 antibodies	were	purchased	 from	Santa	Cruz	Biotechnology	 (TX,	USA)	 for	Rap1A	
(C17),	 Rap1	 (I21),	 HMGCR	 (H‐300),	 GGTase‐I	 (XX‐12),	 GGTase‐II	 (17‐Q),	 FTase	 (H‐300),	
from	 the	 Developmental	 Studies	 Hybridoma	 Bank	 (IA,	 USA)	 for	 MyoG	 (clone	 F5D)	 and	
MYH3	 (F1‐652)	 or	 from	 SigmaAldrich	 for	 β‐actin	 (A5441).	 Appropriate	 secondary	
antibodies	were	purchased	from	Santa	Cruz	Biotechnology.	
2.2. Cell	culture	–	The	human	hepatoma	cell	 line	Huh7	(Nakabayashi	et	al.	1982)	was	a	
kind	 gift	 from	 Steve	 Hood	 (GlaxoSmithKline,	 Ware,	 UK)	 whereas	 the	 human	
rhabdomyeloma	cells	RD	(McAllister	et	al.	1969)	were	purchased	from	the	American	Tissue	
Culture	 Collection	 (CCL‐136).	 Both	 were	 cultured	 in	 Dulbecco’s	 Modified	 Eagle	 Medium	
with	2	mM	L‐glutamine,	4.5	g/L	glucose,	100	units/mL	each	penicillin	and	streptomycin,	
and	 10%	 foetal	 bovine	 serum	 (FBS),	 at	 37˚C	 and	 5%	 CO2.	 RD	 cell	 differentiation	 was	
initiated	by	switching	to	medium	containing	1%	FBS	and	culturing	for	5	days.		
Cells	were	seeded	into	appropriate	vessels	24	h	(Huh7	and	undifferentiated	RD	cells	(RD‐
U))	or	5	days	(differentiated	RD	cells,	RD‐D)	prior	to	treating	with	statins	or	inhibitor	for	
48	 h	 or	 72	 h;	 treatment	was	 carried	 out	 in	 serum‐free	medium	 and	 appropriate	 vehicle	
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controls	 (serum‐free	medium	or	0.1%	dimethylsulfoxide	 (DMSO)	 in	 serum‐free	medium)	
were	included	for	each	treatment.	Cell	viability	was	assessed	by	the	3‐(4,5‐dimethylthiazol‐
2‐yl)2,5‐diphenyl	 tetrazolium	 bromide	 (MTT)	 assay:	 treated	 cells	 and	 controls	 were	
incubated	 with	 0.5	 mg/mL	 MTT	 for	 2½	 h	 and	 the	 resultant	 formazan	 salt	 dissolved	 in	
DMSO	and	 its	absorbance	measured	at	540	nm.	Results	are	expressed	as	a	percentage	of	
vehicle	control;	each	data	point	represents	 the	mean	of	a	minimum	of	 three	independent	
experiments	of	6	wells	per	experiment,	with	error	bars	representing	the	standard	error	of	
the	mean	 (SEM).	 Curves	were	 plotted	 by	 non‐linear	 regression	 and	 compared	 through	 a	
two‐way	 ANOVA	 with	 Tukey’s	 multiple	 comparison	 test,	 using	 GraphPad	 Prism	 (v6,	
GraphPad	Software	Inc.,	La	Jolla,	USA).	
Protein	analysis	–	Total	 protein	was	 extracted	 from	 treated	 and	 control	 cells	 using	RIPA	
buffer	(phosphate	buffered	saline	plus	1%	nonidet	P40,	0.5%	sodium	deoxycholate,	0.1%	
sodium	dodecyl	sulphate,	with	complete	protease	inhibitor	cocktail	(EDTA‐free;	Roche)	as	
previously	described	(Plant	et	al.	2009)	and	the	concentration	measured	by	Lowry	assay	
(Lowry	 et	 al.	 1951).	 Proteins	were	 separated	by	 SDS‐PAGE	 (15	μg	 per	well)	 and	blotted	
onto	PVDF	membrane	before	 immunodetection	using	primary	antibodies	raised	against	a	
variety	of	proteins;	details	of	antibody	concentrations	are	given	in	Supplementary	Table	1.	
Secondary	antibodies	were	 linked	 to	horseradish	peroxidise	and	detection	was	using	 the	
Enhanced	 Chemiluminescence	 (ECL)	 Plus	 reagent	 (GE	Healthcare,	 Bucks,	 UK).	 Computer	
based	 densitometry	 of	 gels	 was	 undertaken	 using	 a	 GeneGenius	 Bioimaging	 System	
(Syngene,	 Frederick,	 MD).	 All	 experiments	 were	 repeated	 on	 at	 least	 three	 independent	
occasions,	 and	 densitometric	 readings	 normalised	 against	 β–actin.	 Statistical	 significance	
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was	 examined	 through	 a	 two‐way	 ANOVA	with	 Tukey’s	multiple	 comparison	 test,	 using	
GraphPad	Prism	(v6,	GraphPad	Software	Inc.,	La	Jolla,	USA).	
2.3. 	
	
3. Results	
3.1. Molecular	markers	differ	between	muscle	and	liver	cell	lines.	
In	the	present	study	we	have	used	the	Huh7	hepatoma	cell	line	to	represent	the	target	cells	
for	the	therapeutic	effects	of	statin	therapy,	and	the	RD	rhabdomyosarcoma	cell	lines	as	a	
surrogate	 target	 cell	 for	 the	myopathic	 adverse	 endpoint.	 Naïve	 RD	 cells	 (RD‐U)	 can	 be	
induced	to	differentiate	 into	a	more	muscle‐like	phenotype	(RD‐D)	by	growth	 in	medium	
containing	reduced	serum	levels.	Differentiation	is	complete	within	5	days,	with	expression	
of	muscle‐specific	markers	myogenin	(MyoG)	and	embryonic	muscle	myosin	heavy	chain	3	
(MYH3)	being	observed	at	both	the	protein	and	transcript	levels	(Fig	2.	and	Supplemental	
Fig.	S1).	Protein	levels	of	MyoG	and	MyH3	were	1.5‐fold	and	1.4‐fold	higher	in	RD‐D	cells	
compared	 to	RD‐U	cells,	 respectively.	 In	addition,	myotube	 formation	was	observed	after	
72	hours	of	differentiation	(Supplemental	Fig.	S1).		
HMGCR,	 the	 target	 enzyme	 for	 statins,	 was	 expressed	 in	 all	 three	 cell	 lines:	 Huh7	 cells	
showed	the	highest	level	of	expression,	being	approximately	1.3‐fold	higher	than	both	RD‐
U	 and	 RD‐D	 cell	 lines	 expression.	 Finally,	 the	 levels	 of	 geranylgeranyl	 transferase	 I	
(GGTase‐I),	GGTase‐II	and	farnesyl	transferase	(FTase)	were	assessed	through	detection	of	
their	specific	β‐subunits:	All	cell	lines	expressed	all	three	prenyltransferase	enzymes,	with	
no	significant	differences	in	expression	levels	observed.		
3.2. Muscle	cells	are	more	sensitive	to	statin	toxicity	than	liver	cells.	
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Following	 initial	 characterisation	of	 the	model	 cell	 lines,	 a	 comprehensive	 comparison	of	
statin	toxicity	was	undertaken	(Fig.	3).	All	statins	elicited	concentration‐dependent	toxicity	
in	each	cell	 line,	although	 in	some	cases	 (e.g.	pravastatin)	 the	concentrations	required	 to	
elicit	 statistically	 significant	 toxicity	 in	 any	 cell	 line	 were	 very	 high	 (mM).	 RD	 cells	
(undifferentiated	 or	 differentiated)	 were,	 generally,	 more	 sensitive	 to	 statin‐mediated	
toxicity	than	Huh7:	A	two‐way	ANOVA	determined	that	RD‐U	cells	were	significantly	more	
sensitive	than	Huh7	cells	to	the	toxic	effects	of	cerivastatin,	simvastatin	(lactone	and	acid)	
and	 fluvastatin	 (p<0.001	 in	 all	 cases),	 atorvastatin	 (p<0.01),	 and	 lovastatin	 (acid)	 and	
pravastatin	 (p<0.05).	 RD‐D	 cells	 were	 significantly	 more	 sensitive	 to	 simvastatin	 (acid;	
p<0.001),	cerivastatin,	atorvastatin	and	rosuvastatin	(all	P<0.01).	In	general,	there	was	no	
significant	 difference	 in	 sensitivity	 of	 RD‐U	 and	 RD‐D	 cells,	 with	 the	 exceptions	 of	
cerivastatin	 (p<0.01)	 and	 the	 lactone	 form	 of	 simvastatin	 (p<0.05);	 in	 both	 cases	
differentiation	reduced	statin	sensitivity.	
IC50	values	for	each	cell	line	were	derived	for	all	statins	where	limiting	solubility	was	not	a	
confounding	factor.	For	cerivastatin,	IC50	values	for	Huh7,	RD‐U	and	RD‐D	were	>100µM,	
2.1	±	0.5µM	and	4.4	±	1.9µM,	respectively;	for	simvastatin	(acid	form)	>100	µM,	2.4	±	0.4µM	
and	0.3	±	0.2µM,	respectively;	and	for	fluvastatin	8.5	±	5.5µM,	6.0	±	1.8µM	and	2.6	±	2.6µM,	
respectively.		
3.3. Lack	of	correlation	between	statin‐dependent	inhibition	of	prenylation	and	cell	toxicity.	
Three	statins	were	chosen	for	further	analysis:	Cerivastatin	was	the	first	statin	withdrawn	
from	 the	market	 for	unacceptable	 toxicity	 and	 caused	 significant	 toxicity	 in	 all	 cell	 lines;	
simvastatin	(acid	form)	represents	the	most	commonly	prescribed	statin,	and	also	caused	
toxicity	in	all	three	cell	lines;	pravastatin	was	significantly	better	tolerated	by	all	three	cell	
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lines,	with	toxicity	not	evident	until	millimolar	concentrations	were	used.	To	examine	the	
potential	 role	 of	 GGTase‐I‐mediated	 prenylation	 in	 statin‐mediated	 toxicity	 we	 used	
geranylgeranylation	 of	 Rap1A	 as	 a	 marker	 for	 this	 enzyme	 activity.	 Under	 normal	
conditions	 almost	 all	 Rap1A	 protein	 is	 prenylated	 in	 all	 model	 cells	 lines,	 with	 no	
unprenylated	 Rap1A	 detectable	 (Fig.	 4).	 Exposure	 of	 all	 three	 cell	 lines	 for	 48	 hours	 to	
cerivastatin	 (1μM)	 or	 simvastatin	 (10μM)	 reduced	 the	 level	 of	 Rap1A	 prenylation	
significantly,	 causing	an	average	7‐fold	 increase	 in	 the	 ratio	of	unprenylated:total	RAP1A	
ratio.	This	phenotype	was	rescued	by	supplementation	with	100µM	mevalonate,	indicating	
it	was	 specifically	due	 to	HMGCR	 inhibition.	By	 contrast,	 exposure	of	 cells	 to	pravastatin	
(10μM)	for	48	hours	had	no	appreciable	impact	on	prenylation	of	Rap1A,	in	any	of	the	cells	
lines	examined.		
Inhibition	 of	 GGT‐I‐mediated	 prenylation	 by	 statins	 was	 concentration	 dependent	 in	 all	
three	 model	 cells	 (Fig.	 5).	 Both	 RD‐U	 and	 RD‐D	 cell	 lines	 showed	 greater	 sensitivity	 to	
statin‐mediated	inhibition	of	Rap1A	prenylation	than	Huh7	cells,	with	a	significant	increase	
in	 the	 unprenylated:total	 RAP1A	 ratio	 detectable	 at	 0.3μM	 	 (cerivastatin)	 and	 3μM	
(simvastatin)	but	at	1μM		(cerivastatin)	and	10μM	(simvastatin,	acid	form)	in	muscle	and	
liver	 cell	 lines,	 respectively.	 This	 is	 consistent	 with	 our	 MTT	 data	 where	 RD	 cells	 were	
significantly	more	sensitive	to	statin‐induced	cytotoxicity	than	Huh7	cells.	However,	in	all	
three	 cell	 types	 unprenylated	 Rap1A	 was	 detected	 at	 approximately	 10‐fold	 lower	
concentrations	 of	 cerivastatin	 than	 simvastatin;	 this	 is	 at	 variance	 with	 our	 MTT	 data,	
where	IC50s	were	either	similar	for	the	two	statins	(RD‐U),	or	lower	for	simvastatin	(acid	
form)	 than	 cerivastatin	 (RD‐D).	 	 Thus,	 whereas	 both	 statins	 caused	 a	 reduction	 in	 cell	
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viability	and	protein	prenylation,	the	lack	of	concordance	in	concentration‐response	data	is	
strongly	supportive	that	these	two	phenomena	are	not	causally	linked.	
To	further	examine	this	apparent	lack	of	concordance	between	statin‐mediated	inhibition	
of	 prenylation	 and	 cell	 death,	 we	 next	 used	 a	 pharmacological	 inhibitor	 of	
prenyltransferases,	GGTI‐2133.	This	compound	inhibits	GGTase‐I	in	vitro	with	an	IC50	of	38	
nM.	 Western	 blot	 analysis	 confirmed	 that	 GGTI‐233	 inhibited	 RAP1A	 prenylation	 in	 a	
concentration	 dependent	manner,	 causing	 increased	 levels	 of	 unprenylated	 Rap1A	 in	 all	
three	 cell	 lines.	 Huh7	 cells	 were	 the	most	 sensitive,	 with	 a	 significant	 change	 in	 Rap1A	
prenylation	 status	 observed	 at	 the	 lowest	 concentration	 examined	 (0.1μM;	 Fig.	 6B).	 In	
contrast,	 both	 muscle	 cell	 lines	 were	 more	 resistant,	 with	 significant	 changes	 in	 the	
unprenylated:total	 RAP1A	 ratio	 not	 observed	 until	 1	 μM.	 GGTI‐2133	 had	 no	 negative	
impact	on	either	cell	viability	 (Fig.	6C)	or	cell	morphology	(Fig.	6D	and	Supplemental	Fig	
S2)	 at	 any	 concentration	 tested	 (maximal	 50µM),	 while	 10µM	 cerivastatin	 caused	
significant	 cell	 death	 and	morphological	 changes	 indicative	of	 apoptosis.	 To	 support	 that	
lack	 of	 toxicity	 with	 GGTI‐2133	 reflected	 a	 target‐specific,	 rather	 than	 chemical‐specific	
effect,	 two	 alternate	 prenyltransferase	 inhibitors	 were	 examined.	 RD‐D	 cells	 exposed	 to	
FTI‐277	(maximal	10µM)	or	perillyl	alcohol	(maximal	500µM)	at	concentrations	producing	
greater	than	99%	inhibition	of	FTase	and	GGTase‐II,	respectively,	also	failed	to	significantly	
impact	on	cell	viability.	Lack	of	toxicity	with	three	different	prenyltransferase	inhibitors	at	
concentrations	exceeding	10x	IC50	for	their	target	prenyltransferase	strongly	supports	the	
hypothesis	that	inhibition	of	prenyltransferases	themselves	is	not	directly	toxic	to	cells.	
		
4. Discussion	
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.	
In	order	to	understand	both	the	mechanisms	of	statin	toxicity	and	the	differences	between	
skeletal	muscle	 and	 liver	 as	 sites	 of	 toxicity	 and	 therapy	 respectively,	we	 have	 used	 cell	
lines	that	represent	the	target	tissues	for	therapeutic	and	adverse	effects.	Huh7	cells	are	a	
hepatoma	cell	line	commonly	used	for	in	vitro	assessment	of	toxicity	and	its	aetiology	(Al‐
Salman	and	Plant	2012;	Elphick	et	al.	2012;	Kolodkin	et	al.	2013;	Kolodkin	et	al.	2010;	Lin	
et	 al.	 2012).	 RD	 cells	 were	 derived	 from	 a	 human	 rhabdomyosarcoma	 and	 represent	 a	
mixture	of	spindle	cells	and	larger	multinucleated	cells;	these	cells	can	also	be	induced	to	
differentiate	into	myotube‐like	structures	by	exposure	to	low	serum	levels	(Knudsen	et	al.	
1998;	Rossi	et	al.	2010).	All	 three	cell	phenotypes	(Huh7,	RD‐U	and	RD‐D)	expressed	the	
target	protein	 for	 statins,	HMGCR,	with	 levels	highest	 in	 liver	 cells.	 Interestingly,	HMGCR	
levels	decrease	during	RD	cell	differentiation,	while	muscle‐specific	markers	increase;	this	
may	reflect	the	lower	requirements	for	synthesis	of	new	membranes	and	generally	 lower	
metabolic	status	of	differentiated	muscle	cells,	which	although	not	entirely	quiescent,	have	
much	lower	rates	of	cell	division	than	in	their	undifferentiated	state.	As	such,	Huh7	and	RD	
cells	represent	good	model	cell	lines	for	examining	the	effect	of	statins	on	liver	and	muscle,	
respectively.		
Since	 one	 of	 the	 principle	 branches	 of	 the	 mevalonate	 pathway	 is	 that	 of	 protein	
prenylation,	 and	 there	has	been	much	 interest	 in	 this	 as	a	possible	mechanism	 in	 statin‐
mediated	 toxicity.	 We	 examined	 the	 levels	 of	 prenyltransferases	 in	 Huh7	 and	 RD	 cells,	
finding	all	three	prenyltransferases	present	at	equivalent	 levels	 in	each	cell	 line.	We	have	
used	Rap1A,	a	member	of	the	Ras‐related	family	of	G‐proteins	that	requires	prenylation	for	
correct	membrane	insertion,	as	a	marker	of	GGTas‐I	activity	(Qian	et	al.	1998;	Wasko	et	al.	
12 
 
2011).	 Under	 normal	 culture	 conditions,	 RAP1A	 is	 fully	 prenylated	 in	 all	 cell	 models,	
despite	 the	 significantly	 lower	 level	 of	HMGCR	present	 in	 RD	 cells.	 This	 suggests	 that	 in	
these	 cell	 lines,	 the	 ability	 to	 process	 prenylated	 proteins	 is	 not	 limited	 by	 rate	 of	
production	of	isoprenoids,	or	the	level	of	the	catalysing	prenyltransferase.	
Reported	 serum	 concentrations	 of	 statins	 during	 standard	 therapy	 are	 reported	 to	 be	
between	2‐15nM,	with	Cmax	concentrations	of	 	8‐40nM	(Bjorkhem‐Bergman	et	al.	2011).	
The	 concentrations	 used	 within	 the	 current	 study	 therefore	 include	 clinically‐relevant	
concentrations,	 although	 it	 should	 be	 noted	 that	 the	 exact	 relationship	 between	 serum	
concentration	 and	 liver/muscle	 concentration	 is	 unclear.	 All	 nine	 of	 the	 statins	 tested	
showed	some	degree	of	concentration‐dependent	toxicity,	mainly	at	doses	that	are	close	to	
that	 observed	 in	 clinical	 therapy.	 The	 exception	 was	 pravastatin,	 where	 toxicity	 only	
occurred	 at	 doses	 in	 the	 millimolar	 range,	 which	 is	 far	 above	 the	 expected	 therapeutic	
concentration.	The	latter	observation	is	likely	to	be	a	mixture	of	both	reduced	toxic	liability	
and	 restricted	 cellular	 access;	 pravastatin	 is	 the	 least	 lipophilic	 of	 all	 the	 statins	 and	 its	
uptake	is	highly	dependent	on	the	expression	of	SLCO1B1	(OATP1B1).	SLCO1B1	is	mainly	
expressed	in	the	liver	(Obaidat	et	al.	2012),	but	its	expression	in	cultured	hepatoma	cells	is	
severely	limited	(Cui	et	al.	2003;	Rodrigues	et	al.	2009).	Rosuvastatin	also	utilises	SLCO1B1	
for	uptake,	but	may	utilise	a	broader	range	of	transporters,	which	may	explain	why	it	still	
exhibits	 toxicity	 (Obaidat	 et	 al.	 2012).	 Other	 statins	 varied	 in	 their	 cytotoxicity,	 with	
cerivastatin	 and	 simvastatin	 showing	 the	 greatest	 toxicity,	 consistent	with	 the	 published	
literature	 (Joshi	 et	 al.	 1999;	 Serajuddin	 et	 al.	 1991).	 It	 should	 be	 noted	 that	 the	 highly	
lipophilic	lactone	forms	of	simvastatin	and	lovastatin	showed	similar	or	lower	toxicity	than	
their	 acid	 forms.	 This	 is	 consistent	with	 a	 requirement	 to	metabolise	 these	 lactone	 pro‐
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drugs	into	their	active	acid	form	prior	to	any	toxic	effect	being	observed.	In	all	cases,	there	
was	more	 toxicity	 observed	 in	 the	muscle	 than	 the	 liver	 cell	 line;	 these	 results	 correlate	
well	 with	 clinical	 data	 for	 these	 drugs	 as	 well	 as	 with	 results	 reported	 in	 the	 literature	
(Mullen	et	al.	2010;	Mullen	et	al.	2011).	One	general	conclusion	is	that	the	statins	appear	to	
be	more	toxic	to	the	muscle	cell	line	(especially	once	differentiated)	compared	to	the	liver	
cell	 line.	 This	 might	 reflect	 a	 cell	 line‐specific	 effect	 and	 not	 be	 related	 to	 the	 tissue	 or	
origin,	with	examination	of	further	cell	lines	experiments	required	to	confirm	this	finding.	
There	are,	however,	two	hypotheses	by	which	muscle	cells	may	be	more	susceptible	to	the	
toxic	effects	of	statins:	First,	the	metabolic	capacity	of	the	liver	is	superior	to	that	of	skeletal	
muscle,	and	while	hepatoma	cell	 lines	have	diminished	metabolic	capacity,	 they	may	still	
possess	 an	 enhanced	 capability	 to	 clear	 the	 statins,	 effectively	 lowering	 the	 intracellular	
concentration	(Plant	2004,	2007).	Second,	due	to	the	role	of	the	liver	in	response	to	toxic	
insult,	 its	repair	systems	(e.g.	 regenerative	capacity,	antioxidant	response	etc.)	are	highly	
developed.	 It	 is	 possible	 that	 liver	 cells	 are	 fundamentally	 more	 robust	 to	 toxicity	 than	
muscle	 cells.	 To	 our	 knowledge	 this	 is	 the	 most	 comprehensive	 comparison	 of	 statins	
across	 cell	 types	 to	 date,	 and	 as	 such	 provides	 an	 important	 resource	 for	 further	
investigations	into	statin‐mediated	effects	in	muscle	and	liver.	
We	further	examined	the	effects	of	cerivastatin,	simvastatin	and	pravastatin	on	prenylation	
in	each	cell	line.	These	statins	represent	the	archetypal	toxic	statin	(cerivastatin),	the	most	
commonly	prescribed	statin	(simvastatin)	and	the	statin	the	 lowest	 toxic	potential	 in	our	
preliminary	 work	 (pravastatin).	 The	 concentration‐dependent	 effect	 of	 cerivastatin,	
simvastatin	 (acid	 form)	 and	 pravastatin	 on	 prenylation	 of	 Rap1A	broadly	 reflected	 their	
relative	toxicity,	with	RD	cells	(both	differentiated	and	undifferentiated)	approximately	3‐
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10‐fold	more	sensitive	 than	Huh7	cells.	 Such	observations	seem	to	support	 the	generally	
accepted	paradigm	 that	 statin‐mediated	 toxicity	 is	prenylation‐dependent	 (Guijarro	et	 al.	
1998;	Matzno	et	al.	2005;	Sakamoto	et	al.	2007;	Sakamoto	et	al.	2011;	Takemoto	and	Liao	
2001).	 However,	 further	 analysis	 argues	 against	 such	 a	 conclusion:	 First,	 relative	
sensitivities	 are	 not	 conserved	 between	 cell	 lines,	 with	 cell	 lines	 approximately	 10‐fold	
more	sensitive	to	prenylation	inhibition	by	cerivastatin	than	simvastatin,	but	the	opposite	
is	seen	with	regards	to	relative	cytotoxicity	(compare	Fig.	5	and	Fig.	3).	Second,	the	specific	
GGTase‐I	 inhibitor	 GGTI‐2133	 caused	 no	 toxicity	when	 used	 at	 concentrations	 providing	
greater	than	99%	inhibition	of	GGTase‐I	in	either	the	liver	or	muscle	cell	lines;	this	was	not	
through	 a	 lack	 of	 cellular	 uptake	 or	 activity	 since	 at	 these	 concentrations	 unprenylated	
Rap1A	was	readily	detected	in	all	cell	types.	These	data	do	not	preclude	the	possibility	that	
toxicity	 is	 through	 disruption	 of	 FTase	 or	 GGTase‐II	 mediated	 prenylation,	 but	 some	
preliminary	comment	can	be	made.	GGTI‐2133	inhibits	GGTase‐I	with	an	IC50	of	38nM,	but	
also	 FTase	 with	 a	 much	 higher	 IC50	 (IC50	 6μM)	 (Johnson	 et	 al.	 2004).	 At	 the	 highest	
concentration	of	GGTI‐2133	used	(10μM),	99%	and	65%	inhibition	of	GGTase‐I	and	FTase‐I	
activity	would	be	achieved,	respectively.	Under	these	conditions,	no	impact	on	cell	viability	
was	 observed	 in	 any	 cell	 line,	 suggesting	 that	 FTase‐mediated	 prenylation	 is	 also	 not	
associated	with	 toxicity.	This	 is	 further	supported	 through	 the	use	of	 the	FTase	 inhibitor	
FTI‐277,	 where	 no	 toxicity	 was	 observed	 at	 concentrations	 that	 would	 cause	 99%	
inhibition	of	both	GGTase‐I	and	FTase	(Lerner	et	al.	1995a).	 .	Finally,	a	similar	absence	of	
cytotoxicity	was	observed	with	the	general	prenylation	inhibitor	perillyl	alcohol	(Hohl	and	
Lewis	 1995).	 	 Further	 experimentation	 would	 be	 required	 to	 confirm	 that	 under	 the	
experimental	 conditions	 used	 inhibition	 of	 GGTase‐II	 and	 FTase‐dependent	 prenylation	
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had	 been	 achieved,	 for	 example	 using	 Rab	 and	 Ras	 family	 members	 as	 specific	 target	
proteins	of	GGTase‐II	and	FTase	respectively	(Lerner	et	al.	1995a;	Zhang	and	Casey	1996).	
However,	given	the	experimental	conditions	are	 those	previously	shown	to	disrupt	 these	
enzymes	in	vitro,	it	is	probable	that	this	has	been	achieved	in	the	current	study.		
The	evidence	here	supports	the	hypothesis	that	 inhibition	of	prenylation	by	statins	is	not	
causative	of	 the	 toxicity	 seen	 in	muscle	and	 liver	 cells.	However,	 it	 cannot	be	discounted	
that	 there	 is	 a	 higher‐order	 interaction	occurring	between	different	 cell‐types	 or	 organs,	
meaning	that	in	vitro‐in	vivo	extrapolation	is	compromised.	To	examine	such	a	possibility	
would	 require	 animal	 experimentation,	 and	 the	 data	 provided	 herein	 supports	 such	 a	
course	 of	 action.	 Presuming	 that	 inhibition	 of	 prenylation	 and	 toxicity	 are	 causally	
disassociated,	it	is	interesting	to	speculate	on	alternate	mechanisms.	As	previously	stated,	
the	 alternative	 metabolic	 endpoints	 from	 the	 mevalonate	 pathway	 are	 the	 formation	 of	
isoprenoids,	ubquinone	and	dolichol.	Given	 that	mevalonate	 can	 rescue	cells	 from	statin‐
mediated	 toxicity,	 it	 is	 logical	 to	 hypothesise	 that	 one	 of	 the	 alternate	metabolic	 fates	 is	
central	to	the	observed	toxicity.	Evidence	exists	to	support	both	disruption	of	ubiquinone	
(Marcoff	and	Thompson	2007)	and	dolichol‐mediated	N‐linked	glycosylation	(Mullen	et	al.	
2010;	Siddals	et	al.	2004).	At	present	these	areas	have	been	poorly	examined	compared	to	
prenylation,	 and	 should	 not	 be	more	 fully	 explored.	 Together,	 these	 data	 are	 consistent	
with	the	conclusion	that	statin‐mediated	inhibition	of	prenyltransferases	is	not	responsible	
for	the	observed	toxicity	of	statins.		
5. Conclusion	
In	the	present	study	we	have	carried	out	a	comprehensive	comparison	of	statin	effects	in	
two	 cell	 lines,	 representing	 liver	 and	muscle	 phenotypes.	Our	 data	 show	 that	 statins	 are	
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more	 potent	 toxins	 towards	 muscle	 compared	 to	 liver	 cell	 phenotypes,	 and	 that	 this	 is	
likely	to	be	a	consequence	of	reduced	capacity	in	the	mevalonate	pathway	in	this	cell	type.	
In	 addition,	we	 provide	 strong	 evidence	 to	 counter	 the	 assumption	 that	 statin‐mediated	
inhibition	 of	 prenylation	 is	 responsible	 for	 the	 observed	 toxicity.	 In	 vivo	 analysis	 should	
now	be	undertaken	to	confirm	these	findings	in	a	whole	animal	setting.	
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Figure	Legends	
	
Figure	1:	The	mevalonate	pathway.	Principle	 products	 are	 in	 boxes.	 Key	 enzymes	 are	
shown	 in	 italics,	 with	 relevant	 inhibitors	 in	 square	 brackets.	 Multistep	 processes	 (for	
instance	 in	 the	production	of	cholesterol	 from	 lanosterol)	are	 indicated	with	dotted	 lines	
and	arrows	
	
Figure	2:	Basal	comparisons	of	Huh7	and	RD	 cells.	Total	 protein	was	 extracted	 from	
Huh7,	 undifferentiated	 RD	 (RD‐U)	 or	 differentiated	 RD	 (RD‐D).	 Specific	 proteins	 were	
detected	 immunologically	 using	 antibodies	 and	 conditions	 as	 given	 in	 the	 methods.	 A	
representative	 blot	 is	 shown	 in	 (A),	 with	 quantitation	 of	 triplicate	 independent	 repeats	
provided	in	(B).	Error	bars	=	S.E.M	and	***=p<0.001	for	indicated	comparison.		
Figure	3:	 Liver	 and	muscle	 cell	 lines	 show	differential	 sensitivity	 to	 statins.	Huh7,	
undifferentiated	RD	(RD‐U)	or	differentiated	RD	(RD‐D)	were	exposed	for	48	h	with	statins	
or	appropriate	vehicle	controls	(0.1%	DMSO	or	medium	alone).	Cell	viability	was	measured	
by	 MTT	 assay	 and	 is	 expressed	 as	 a	 percentage	 of	 vehicle	 control.	 Each	 data	 point	
represents	the	mean	of	three	independent	experiments.	Error	bars	represent	the	standard	
error	of	the	mean	(SEM).	Circular	data	points	with	solid	 lines	=	Huh7;	square	data	points	
with	hatched	lines	=	RD‐U;	diamond	data	points	with	dotted	lines	=	RD‐D	
	
Figure	4:	Effect	of	statin	treatment	on	Rap1A	prenylation.	Total	protein	was	extracted	
from	Huh7,	undifferentiated	RD	(RD‐U)	or	differentiated	RD	(RD‐D)	exposed	for	48	hours	
to	 statin	 (10	µM	 for	 simva‐	 and	pravastatin,	 or	1	µM	cerivastatin),	 vehicle	 control	 (0.1%	
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DMSO	or	serum	free	medium)	or	mevalonate	(100	µM)	plus	statin.	Protein	was	analysed	by	
Western	 blotting	 using	 antibodies	 against	 the	 unprenylated	 form	 of	 Rap1A,	 total	 Rap1A	
protein	 	 and	β‐actin	 as	 a	 loading	 control.	A	 representative	blot	 is	 shown	 in	 (A),	with	 the	
prenylated:total	RAP1A	ratio	from	three	independent	repeats	provided	in	(B).	Error	bars	=	
S.E.M,	and	***=p<0.001	for	indicated	comparison.	
	
	
Figure	 5:	 Sensitivity	 of	 Rap1A	 prenylation	 to	 HMGCR	 inhibition	 varies	 between	
statins	and	cell	lines.	Total	protein	was	extracted	from	Huh7,	undifferentiated	RD	(RD‐U)	
or	differentiated	RD	(RD‐D)	cells,	following	treatment	for	48	h	with	varying	concentrations	
of	simvastatin	(left	panels)	or	cerivastatin	(right	panels).	Protein	was	analysed	by	Western	
blotting	using	antibodies	 to	 the	unprenylated	 form	of	Rap1A,	 total	Rap1A	protein	and	β‐
actin	as	a	 loading	control.	A	representative	blot	is	shown	in	(A),	with	the	prenylated:total	
RAP1A	 ratio	 from	 three	 independent	 repeats	 provided	 in	 (B).	 Error	 bars	 =	 S.E.M,	 and	
*=p<0.05,	**=p<0.01,	***=p<0.001	versus	vehicle	control.	
	
Figure	6:	Prenyltransferase	 inhibitors	do	not	 impact	on	 cell	 viability.	Total	 protein	
was	extracted	from	Huh7,	undifferentiated	RD	(RD‐U)	or	differentiated	RD	(RD‐D)	exposed	
for	72h	to	the	GGTase‐I	inhibitor	GGTI‐2133.	GGTase‐I	mediated	prenylation	was	assessed	
by	Western	 blotting	 using	 antibodies	 against	 Rap1A	 (unprenylated),	 total	 Rap1A	 and	 β‐
actin	 .	A	 representative	blot	 is	 shown	 in	 (A),	with	 the	prenylated:total	RAP1A	 ratio	 from	
three	 independent	 repeats	provided	 in	 (B).	Cell	viability	was	assessed	by	MTT	assay	 (C),	
and	morphological	changes	assessed	by	light	microscopy	at	400x	magnification	(D).	Finally,	
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RD‐D	cells	were	exposed	to	the	alternate	prenyltransferase	inhibitors	FTI‐277	and	perillyl	
alcohol	at	 the	 indicated	 concentrations	 for	72	h	and	cell	 viability	assessed	by	MTT	assay	
(E).	Error	bars	=	S.E.M,	n=3,	and	**=p<0.01,	***=p<0.001	versus	vehicle	control.		
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